| Ytd | -10.10% | |
| 1y | -64.18% |
| Open | 0.70 | Prev Close | 0.70 | Low | 0.67 | High | 0.71 | Mkt Cap | 17.27M |
| Vol | 12.47K | Avg Vol | 154.57K | EPS | -0.51 | P/E | -1.36 | Forward P/E | -2.27 |
| Beta | 1.58 | Short Ratio | 2.01 | Inst. Own | 0.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-08 | 50-d Avg | 0.76 | 200-d Avg | 0.89 | 1yr Est | 7.50 |
The planned submission follows alignment with Health Canada on the NDS pathway and is supported by a
First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reducti
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnol
Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $1